Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(21 sites)

United States

Arkansas Children's, Little Rock, Arkansas

Sean N. Parker Center for Allergy and Asthma Research, Palo Alto, California

Asthma & Allergy Associates, P.C., Colorado Springs, Colorado

National Jewish Health, Denver, Colorado

Children's National Hospital, Washington D.C., District of Columbia

University of South Florida, Tampa, Florida

Children's Healthcare of Atlanta - Center for Advanced Pediatrics, Atlanta, Georgia

Boston's Children's Hospital, Boston, Massachusetts

Clinical Research Institute, Inc, Minneapolis, Minnesota

Northwell Health, Great Neck, New York

University of North Carolina at Chapel Hill Clinical and Translational Research Center( CTRC), Chapel Hill, North Carolina

Australia

St Vincent's Hospital Sydney, Darlinghurst, New South Wales

Children's Hospital at Westmead, Westmead, New South Wales

Queensland Children's Hospital, South Brisbane, Queensland

Women's & Children's Hospital, North Adelaide, South Australia

Monash Medical Centre, Clayton, Victoria

Royal Melbourne Hospital, Parkville, Victoria

Perth Children's Hospital, Nedlands, Western Australia

Fiona Stanely Hospital, Perth, Western Australia

Canada

Halton Pediatric Allergy, Burlington, Ontario

Ottawa Allergy Research Corporation, Ottawa, Ontario